SCHEDULE 13G/A: BlackRock Discloses 8.2% Stake in Castle Biosciences Inc. Through Latest SEC Filing
Beneficial Ownership Report
BlackRock, Inc. has filed an Amendment No. 4 to Schedule 13G, reporting a beneficial ownership of 8.2% of Castle Biosciences Inc.'s common stock as of March 31, 2025.
Summary
- BlackRock, Inc. filed an Amendment No. 4 to Schedule 13G regarding its beneficial ownership in Castle Biosciences Inc.
- As of March 31, 2025, BlackRock beneficially owns 2,338,005 shares of Castle Biosciences Inc. common stock.
- This represents 8.2% of the total outstanding common stock of Castle Biosciences Inc.
- BlackRock holds sole voting power over 2,297,650 shares and sole dispositive power over 2,338,005 shares.
- The filing indicates that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
- Several BlackRock subsidiaries are identified as potentially holding 5% or more of the outstanding shares, including BlackRock Advisors, LLC and BlackRock Investment Management (UK) Limited.
Sentiment
Score: 6
Explanation: The document is a routine regulatory filing. The continued significant stake by a major institutional investor like BlackRock is generally a positive signal, indicating confidence in the company, hence a slightly positive score.
Positives
- A major institutional investor, BlackRock, maintains a significant stake (8.2%) in Castle Biosciences Inc., which can be interpreted as a vote of confidence in the company's long-term prospects.
- The holding is for investment purposes in the ordinary course of business, not for control, suggesting a stable, passive investment.
Future Outlook
The document does not provide any forward-looking statements or guidance regarding Castle Biosciences Inc.'s future performance or BlackRock's future investment intentions beyond the current beneficial ownership.
Industry Context
This filing is a standard disclosure by a large asset manager, BlackRock, indicating its passive investment in a biotechnology company, Castle Biosciences Inc. It reflects BlackRock's broad investment strategy across various sectors rather than a specific trend within the biotechnology industry itself.
Stakeholder Impact
- Shareholders of Castle Biosciences Inc. may view BlackRock's continued significant stake as a positive indicator of institutional confidence in the company's value and prospects.
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Previous Power of Attorney date, which was revoked. |
| 2025-01-21 | Effective date of the new Power of Attorney for BlackRock's filing purposes. |
| 2025-03-31 | Date of event which requires filing of this statement (reporting date for ownership). |
| 2025-04-23 | Date of filing/signature date of the Schedule 13G Amendment No. 4. |
Keywords
BlackRock, Castle Biosciences Inc., Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Equity Stake, Investment Management
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.